FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213303508> ?p ?o ?g. }

• W3213303508 endingPage "4066" @default.
• W3213303508 startingPage "4066" @default.
• W3213303508 abstract "Abstract INTRO: Immune profiles and immune reconstitution are increasingly studied as important contributors to the prognosis and treatment responses of hematologic malignancy patients. Data on epidemiologic factors influencing immune profiles in hematologic malignancy patients are lacking. METHODS: We performed flow cytometric analyses of immune panels including T-cell, B-cell, NK cell and dendritic cell (DC) subsets in 1,025 consecutive adult hematologic malignancy patients (N=873) and controls/donors (N=152) between 2006-2016. Immune panels were analyzed on fresh peripheral blood samples drawn during workup before autologous or allogeneic hematopoietic cell transplant (HCT). Hematologic malignancy diagnoses were AML (N=235), MM (N=228), NHL (N=197), MDS/MPN (N=85), ALL (N=60), HL (N=33) and other leukemias (N=35). Patients were 58% male, median age 58 years (range 18-77), 91% non-Hispanic white (NHW), 6% African-American (AA), 1.3% Hispanic, 1.5% other. The HCT-comorbidity index (HCT-CI) in patients showed: 63% with &gt; 1 co-morbidity; 26% moderate pulmonary, 22% psychologic (requiring therapy/counseling), 16% severe pulmonary, 12% cardiac (CHF/CAD/MI), 11% diabetes requiring insulin, 9% obese (BMI&gt;35mg/kg 2), 9% prior cancer. Controls were related apheresis or marrow donors of allogeneic HCT patients: 51% male, median age 49 years (range 19-73), 92% NHW, 4% AA, 1.3% Hispanic, 2.6% other. HCT-CI scoring of controls: 45% with &gt; 1 comorbidity, 20% obese, 20% psychologic, 10% mild liver disease, 7% diabetes. Due to inter-individual cell count variability, immune cells were normalized as percent gated of lymphocytes except DC populations which were gated on mononuclear cells, both on forward and side scatter. To control for multiple comparisons, Bonferroni corrected statistically significant P was set at &lt;0.001. RESULTS: In controls, males had a significantly lower proportion of CD3+ cells/µl than females (68% vs 73%, P=0.001), NHW had a higher proportion of CD8+ central memory (CM) cells than other race/ethnicities (4.6 vs 2.7%, P=0.004) with no other significant differences by sex or race, although some of the race groups were low in our cohort. In contrast, among hematologic malignancy patients, males had significantly lower CD4+, CD4+ naïve, CD4+ recent thymic emigrants (RTEs), total T-regulatory cells (Treg), and CD19+ naïve cells but significantly higher CD8+ CM and effector memory (EM) cells than females. In addition, NHW had higher CD8+ CM than AA, Hispanic and Other races. Significant differences by age in patients and controls are shown in the Table. Across all age groups, patients had higher proportions of CD3+ cells, lower proportions of B-cells and no difference in NK or DCs than controls. As controls increased in age, CD4+ total significantly increased, while CD8+total, CD8+naive, T-γδ cells decreased, and myeloid DCs were highest at each end of the age spectrum. As patients increased in age, activated HLA-DR T-cells significantly increased, while T-γδ, CD8+naïve, and RTEs significantly decreased. The CD4:8 ratio increased while the CD4+ and CD8+ naïve:EM ratio decreased with age in both controls and patients, however patients had lower CD4:CD8 and naïve:EM ratios than controls. Immunophenotypes by patient disease are shown in the Figure. In general, patients with lymphoid diseases had lower CD3+CD4+ but higher CD3+CD8+, NK and DCs. In controls/donors, there were no significant differences in immune cell profiles by the presence or absence of comorbidities: obesity, diabetes, psychologic and mild liver disease. In patients, T-γδ were significantly lower in patients with diabetes, with no other significant differences for cardiac, psychologic, prior cancer, obesity or pulmonary co-morbidities. CONCLUSIONS: Additional analyses are ongoing to investigate the influence of prior therapies (chemotherapy, hypomethylating agents, monoclonal antibodies, etc.) and cytogenetic risk groups within each disease (AML, ALL, MDS/MPN, MM, NHL) on immune cell profiles. Studies of immunophenotyping in hematologic malignancies should include adjustment for confounders such as age, sex and race as biologic variables, as well as consideration of the diseases and treatments given. Interestingly, common co-morbidities did not broadly influence immune cell profiles in our cohort of hematologic malignancy patients. Figure 1 Figure 1. Disclosures Chen: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium. Hillengass: Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Beijing Medical Award Foundation: Speakers Bureau; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Beijing Life Oasis Public Service Center: Speakers Bureau; Skyline: Membership on an entity's Board of Directors or advisory committees; Curio Science: Speakers Bureau; Adaptive: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Oncotracker: Membership on an entity's Board of Directors or advisory committees; Axxess Network: Membership on an entity's Board of Directors or advisory committees. Wang: Genentech: Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Consultancy, Speakers Bureau; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Other: Advisory Board; Mana Therapeutics: Consultancy, Honoraria; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kura Oncology: Consultancy, Honoraria, Other: Advisory board, steering committee, Speakers Bureau; GlaxoSmithKline: Consultancy, Honoraria, Other: Advisory Board; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Kite Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Pfizer: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; Stemline Therapeutics: Consultancy, Honoraria, Other: Advisory board, Speakers Bureau; Takeda: Consultancy, Honoraria, Other: Advisory board; Rafael Pharmaceuticals: Other: Data safety monitoring committee; Gilead: Consultancy, Honoraria, Other: Advisory board; Daiichi Sankyo: Consultancy, Honoraria, Other: Advisory board; PTC Therapeutics: Consultancy, Honoraria, Other: Advisory board; Genentech: Consultancy; MacroGenics: Consultancy. Griffiths: Takeda Oncology: Consultancy, Honoraria; Alexion Pharmaceuticals: Consultancy, Research Funding; Apellis Pharmaceuticals: Research Funding; Abbvie: Consultancy, Honoraria; Astex Pharmaceuticals: Honoraria, Research Funding; Genentech: Research Funding; Taiho Oncology: Consultancy, Honoraria; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Boston Biomedical: Consultancy. Torka: TG Therapeutics: Membership on an entity's Board of Directors or advisory committees. McCarthy: Bluebird: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Juno: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W3213303508 created "2021-11-22" @default.
• W3213303508 creator A5008947160 @default.
• W3213303508 creator A5016042168 @default.
• W3213303508 creator A5031293676 @default.
• W3213303508 creator A5038660651 @default.
• W3213303508 creator A5050643493 @default.
• W3213303508 creator A5052906436 @default.
• W3213303508 creator A5055162501 @default.
• W3213303508 creator A5060452476 @default.
• W3213303508 creator A5063351800 @default.
• W3213303508 creator A5065404552 @default.
• W3213303508 creator A5066598802 @default.
• W3213303508 creator A5068472643 @default.
• W3213303508 creator A5078571628 @default.
• W3213303508 creator A5078600949 @default.
• W3213303508 creator A5081052884 @default.
• W3213303508 creator A5085526628 @default.
• W3213303508 date "2021-11-05" @default.
• W3213303508 modified "2023-09-30" @default.
• W3213303508 title "Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients" @default.
• W3213303508 doi "https://doi.org/10.1182/blood-2021-150954" @default.
• W3213303508 hasPublicationYear "2021" @default.
• W3213303508 type Work @default.
• W3213303508 sameAs 3213303508 @default.
• W3213303508 citedByCount "0" @default.
• W3213303508 crossrefType "journal-article" @default.
• W3213303508 hasAuthorship W3213303508A5008947160 @default.
• W3213303508 hasAuthorship W3213303508A5016042168 @default.
• W3213303508 hasAuthorship W3213303508A5031293676 @default.
• W3213303508 hasAuthorship W3213303508A5038660651 @default.
• W3213303508 hasAuthorship W3213303508A5050643493 @default.
• W3213303508 hasAuthorship W3213303508A5052906436 @default.
• W3213303508 hasAuthorship W3213303508A5055162501 @default.
• W3213303508 hasAuthorship W3213303508A5060452476 @default.
• W3213303508 hasAuthorship W3213303508A5063351800 @default.
• W3213303508 hasAuthorship W3213303508A5065404552 @default.
• W3213303508 hasAuthorship W3213303508A5066598802 @default.
• W3213303508 hasAuthorship W3213303508A5068472643 @default.
• W3213303508 hasAuthorship W3213303508A5078571628 @default.
• W3213303508 hasAuthorship W3213303508A5078600949 @default.
• W3213303508 hasAuthorship W3213303508A5081052884 @default.
• W3213303508 hasAuthorship W3213303508A5085526628 @default.
• W3213303508 hasBestOaLocation W32133035081 @default.
• W3213303508 hasConcept C121608353 @default.
• W3213303508 hasConcept C126322002 @default.
• W3213303508 hasConcept C194409129 @default.
• W3213303508 hasConcept C203014093 @default.
• W3213303508 hasConcept C2779134260 @default.
• W3213303508 hasConcept C2779399171 @default.
• W3213303508 hasConcept C2780571819 @default.
• W3213303508 hasConcept C2908731994 @default.
• W3213303508 hasConcept C2909813644 @default.
• W3213303508 hasConcept C2909984355 @default.
• W3213303508 hasConcept C59822182 @default.
• W3213303508 hasConcept C71924100 @default.
• W3213303508 hasConcept C76509639 @default.
• W3213303508 hasConcept C86803240 @default.
• W3213303508 hasConcept C8891405 @default.
• W3213303508 hasConceptScore W3213303508C121608353 @default.
• W3213303508 hasConceptScore W3213303508C126322002 @default.
• W3213303508 hasConceptScore W3213303508C194409129 @default.
• W3213303508 hasConceptScore W3213303508C203014093 @default.
• W3213303508 hasConceptScore W3213303508C2779134260 @default.
• W3213303508 hasConceptScore W3213303508C2779399171 @default.
• W3213303508 hasConceptScore W3213303508C2780571819 @default.
• W3213303508 hasConceptScore W3213303508C2908731994 @default.
• W3213303508 hasConceptScore W3213303508C2909813644 @default.
• W3213303508 hasConceptScore W3213303508C2909984355 @default.
• W3213303508 hasConceptScore W3213303508C59822182 @default.
• W3213303508 hasConceptScore W3213303508C71924100 @default.
• W3213303508 hasConceptScore W3213303508C76509639 @default.
• W3213303508 hasConceptScore W3213303508C86803240 @default.
• W3213303508 hasConceptScore W3213303508C8891405 @default.
• W3213303508 hasIssue "Supplement 1" @default.
• W3213303508 hasLocation W32133035081 @default.
• W3213303508 hasOpenAccess W3213303508 @default.
• W3213303508 hasPrimaryLocation W32133035081 @default.
• W3213303508 hasRelatedWork W2025807460 @default.
• W3213303508 hasRelatedWork W2051661648 @default.
• W3213303508 hasRelatedWork W2063340637 @default.
• W3213303508 hasRelatedWork W2175332343 @default.
• W3213303508 hasRelatedWork W2353170375 @default.
• W3213303508 hasRelatedWork W2404070609 @default.
• W3213303508 hasRelatedWork W2805113298 @default.
• W3213303508 hasRelatedWork W2970767694 @default.
• W3213303508 hasRelatedWork W2977651228 @default.
• W3213303508 hasRelatedWork W4226248843 @default.
• W3213303508 hasVolume "138" @default.
• W3213303508 isParatext "false" @default.
• W3213303508 isRetracted "false" @default.
• W3213303508 magId "3213303508" @default.
• W3213303508 workType "article" @default.